Generic name:rosuvastatin (rosuvastatin calcium; 10 mg; 20 mg) [rosuvastatin calcium]Brand names:,,,,,Dosage form:oral tablet, oral suspensionDrug class:
Medically reviewed by. Last updated on Jul 16, 2024.
Rosuvastatin belongs to a class of medications calledstatins. It works by blocking certain natural substances (i.e., certain proteins in the body) from being synthesized, and then reducing the amount of these proteins produced by the body. It is used to help treat high blood pressure and to lower cholesterol.
Rosuvastatin is used to treat heart failure and to lower high blood pressure in people with heart failure. It can also be used to treat symptoms of edema (fluid retention) associated with congestive heart failure.
Rosuvastatin is also used to treat cholesterol (also called LDL cholesterol) and to treat people who have high cholesterol. Rosuvastatin should not be used to prevent heart attack or stroke, if you have heart disease, high blood pressure, or kidney disease.
This medication is not indicated for people with a history of heart attack, stroke, or heart failure.
This medication may be used for other uses; ask your doctor or pharmacist for more information.
This medication should not be used by anyone under 18 years old who is pregnant, may become pregnant, or has had a stroke, heart attack, or heart failure.
Do not let anyone else use this medication without first talking to your doctor.
This medication may cause a condition calledhypersensitivity to the drugorallergy to any of the ingredients in this medicationThis may cause a reaction calledallergy to any component in this medication
Before taking this drug, tell your doctor and pharmacist if you are allergic to rosuvastatin, raloxifene, any other medications, or any other ingredients in this medication.
Before using this medication, tell your doctor or pharmacist your medical history, especially of:
blood disorders including leukemia
blood vessel disease such as angioedema
heart failure
heart disease
high cholesterol
high blood pressure
high levels of fibrinolyticin people with a history of heart failure
This medication may increase the level of fibrinolytic, especially when used in combination with acetazolamide (the active ingredient in this medication), an all-day therapy (blood pressure lowering, antifibrinolytic, and antiplatelet).
The medication can cause a serious reaction called
Eli Lilly has spent more than $1 billion selling its blockbuster cholesterol drug Crestor in the United States in the last three years, and it will pay off at least another $1.2 billion to settle lawsuits filed by people who have been charged with distributing the medication to children and teenagers.
The case, filed Friday in the U. S. District Court for the District of New Jersey, involves a group of women who have been diagnosed with a rare form of breast cancer known as non-small cell lung cancer (NSCLC).
The women have been diagnosed with the disease after receiving prescription drug treatment from a doctor. They were prescribed the drug for the first time in their lives, but because of the potential for serious side effects, the doctors said they were only able to write prescriptions for one of the drugs for which they had been prescribed. They were prescribed two other drugs for the same condition, and the women were required to pay for one of them, the judge said.
The women have already pleaded guilty and have been appealing the decision, which was announced Monday at the U. Food and Drug Administration's annual meeting.
"We are very disappointed with the outcome of this case and I am satisfied with the outcome of this case," said Steven Stapleton, spokesman for the company that brought the drug to the market in 2001. "We believe we've come to the right position in this case because we believe that these women have been harmed by the use of Crestor, which is approved by the FDA and is currently in a class of drugs known as statins. This is a life-changing drug, one that is life-changing for all of us."
The women were treated with Crestor, a generic version of the popular statin Lipitor, in 2006. They began taking the drug in January and are now taking two doses. The women are expected to take Crestor for six months, which is the standard of care for their diagnosis.
The women have been taking the drug for about three years now, Stapleton said.
The women were also prescribed the drug for an allergic reaction after taking a steroid product called Zocor, which causes an allergic reaction.
They were told Crestor caused their breasts to swell. They were told it could not be removed because of the side effects and they were told they had to stop taking the drug in order to stop their health problems. They were also told they were being treated with the same drug, which was also prescribed to them by a doctor.
The women had been prescribed the drug because of the potential for serious side effects. They were told it could not be removed because of the side effects.
"We are disappointed with the outcome of this case and we are going to move forward with our plan," Stapleton said. "We are not happy with the outcome of this case because we believe that these women have been harmed by the use of Crestor, which is approved by the FDA and is currently in a class of drugs known as statins."
Stapleton and his wife, Susan, have filed a joint statement with the plaintiffs' attorneys.
Copyright 2025 First Call | All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Contact:David M. Stapleton, 301-778-6500 or
|Web site: www.lilly.comReferences:
Stapleton, Steven. Crestor, cholesterol drug. In: Stapleton, Steven, 2009. "Crestor: The Complete Guide to Prescribing,"FDA Prescribing Information, accessed July 24, 2019.Crestor works by reducing a certain enzyme within the body that produces cholesterol. It belongs to a class of medications called statins.
Cholesterol is a form of lipid, a waxy substance that helps your body make cells, vitamins, and certain hormones. It is not inherently bad. Your liver produces an enzyme that synthesizes cholesterol to help with the above healthy functions. Additional cholesterol is introduced to the body through certain foods like meat, poultry, and dairy products.
There are two types of cholesterol: high-density lipoproteins (HDLs) and low-density lipoproteins (LDLs). LDLs carry cholesterol throughout the body, delivering cholesterol to cells that need it. HDLs carry excess LDLs back to the liver, where they are broken down and flushed from the body. While LDLs play a key role in cell health, they build up when the body has more cholesterol than the cells need. This buildup turns into plaque in the arteries (blood vessels). As plaque covers the artery walls, the blood vessels become narrow. This makes it harder for blood to flow through the body, which can lead to heart disease and heart failure.
Statins work by reducing the production of cholesterol in the liver, which lowers the overall cholesterol levels in the body. Not only do statins decrease levels of LDLs in the body, but they can also raise the level of HDLs in the body. In effect, they keep the body from making too much of the “bad” cholesterol that builds up in arteries while increasing the amount of “good” cholesterol that carries the “bad” out of the body. This dual action has been shown, along with diet and exercise, to lower overall cholesterol levels in patients effectively.
Crestor (rosuvastatin) is an effective medicine used to treat a variety of symptoms in patients that may be caused by a lack of cholesterol in the body. For example, it can cause the following symptoms:Symptoms of hepatitis include persistent increased liver enzymes, muscle stiffness, and yellowing of the skin or eyes. Statins like lopinavir can help speed up this process and reduce the chance of complications like hepatic scarring or infections.
A common side effect of Crestor is muscle stiffness, which can be treated with specific exercises or dietary adjustments. However, Crestor can also help improve the liver’s ability to make cholesterol. Not only can this side effect occur, but it can lead to liver disease in some individuals. This condition can impact the health of both the individual and their family.
Crestor (rosuvastatin) (rosuvastatin) (c) 1997 Nov 30(14):15-21arger is not necessarily better.
In a recent, Dr. Steven Nissen of the University of Illinois at Chicago (UIC) and colleagues assessed the effects of rosuvastatin (Crestor) on lipid parameters in patients with high cholesterol. They used the American Type 2 Diabetes Study (ATLS) on behalf of the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) to assess the lipid profile in patients with type 2 diabetes with and without hyperlipidemia. Using data from the ATLS, they analyzed the effect of the drug on blood lipids in a large sample of patients with and without hyperlipidemia. They found that patients with high cholesterol had greater reductions in the total cholesterol (TLDL) and low density lipoprotein (LDL) cholesterol levels and an increased risk of death, hospitalization for acute myocardial infarction (MI), and stroke. The reduction in TLDL and LDL cholesterol levels was not associated with a reduction in the risk of death, hospitalization for MI, or stroke. In addition, patients with high cholesterol had a greater rate of nonfatal MI, nonfatal stroke, hospitalization for acute myocardial infarction, and nonfatal stroke compared to patients with normal cholesterol levels. Patients with hyperlipidemia had a greater percentage of patients with an increased risk of death and hospitalization for acute myocardial infarction. These findings suggest that the lipid profile of patients with hyperlipidemia with and without hyperlipidemia may not predict the risk for death, hospitalization for MI, and stroke, regardless of cholesterol level. The data do not suggest that patients with high cholesterol with or without hyperlipidemia have an increased risk of cardiovascular disease or death.
Dr. Steven NissenThe ATLS was a prospective study of 1,906 patients with type 2 diabetes and dyslipidemia who were randomized to rosuvastatin 10 mg/day or placebo. The primary outcome measure was the change in lipid levels and the secondary outcome measures were cardiovascular mortality, MI, hospitalization for acute myocardial infarction, and stroke. The ATLS was a randomized, double-blind, placebo-controlled, multicenter study with a total of 2,051 patients, with dyslipidemia and hypercholesterolemia. The primary endpoint was change in lipid levels and the secondary endpoints included all-cause mortality, MI, and stroke. A total of 1,906 patients completed the study and the primary and secondary endpoints were the risk of death, MI, and stroke, and the risk of hospitalization for acute myocardial infarction, stroke, and nonfatal stroke. There were 10.4% (n = 1,906) and 8.2% (n = 1,069) of patients with dyslipidemia and hypercholesterolemia had a 5% or greater change in their TLDL and LDL cholesterol levels, respectively. The effect of rosuvastatin on lipid levels was not different in patients with and without hypercholesterolemia. These results suggest that rosuvastatin may be a useful adjunct to diet in patients with high cholesterol and hypercholesterolemia. However, it should be noted that this study did not examine the effect of rosuvastatin on other lipid profile parameters. A recent retrospective study of patients with dyslipidemia and hypercholesterolemia found that rosuvastatin is not associated with an increased risk of death, hospitalization for MI, or stroke. These findings suggest that rosuvastatin may be beneficial in patients with hypercholesterolemia and those with a normal cholesterol level.
The ATLS was a study of 2,051 patients with hyperlipidemia and dyslipidemia who were randomized to rosuvastatin 10 mg/day or placebo. The primary outcome measure was the change in cholesterol and triglyceride levels.
Stade de France Pharmacy